Silence Therapeutics plc SLN
We are a biotechnology company focused on discovering and developing novel molecules incorporating short interfering ribonucleic acid, or siRNA, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Our siRNA molecules are designed to harness the body's natural mechanism of RNAi by specifically binding to and degrading messenger RNA, or mRNA, molecules that encode specific targeted disease-associated proteins in a cell. By degrading the message that encodes the disease-associated protein, the production of that protein is reduced and its level of activity is lowered. In the field of RNAi therapeutics, this reduction of disease-associated protein production and activity is referred to as "gene silencing." Our proprietary mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform consists of siRNA product candidates designed to precisely target and ‘silence' specific disease-associated genes in the liver. Using our mRNAi GOLD platform, we have generated siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate.
SLN is a depositary receipt: one SLN stands for 3 shares of this company, per the cover page of its latest 10-K. The market cap and the multiples above are stated per receipt; the statements below, including EPS, are as filed and are per underlying share.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $559.0K | $43.3M | $31.6M | $21.7M | — | — |
| Cost of revenue | $215.0K | $11.8M | $12.9M | $13.5M | — | — |
| Gross profit | $344.0K | $31.4M | $18.8M | $8.2M | — | — |
| R&D | $67.8M | $67.9M | $56.9M | $43.5M | — | — |
| SG&A | $22.3M | $26.9M | $26.2M | $25.7M | — | — |
| Operating income | -$91.1M | -$63.3M | -$64.4M | -$61.0M | — | — |
| Pre-tax income | -$88.6M | -$44.5M | -$53.3M | -$49.6M | — | — |
| Income tax | $11.0K | $845.0K | $956.0K | $688.0K | — | — |
| Net income | -$88.6M | -$45.3M | -$54.2M | -$50.3M | — | — |
| EPS, basic | -0.63 | -0.33 | -0.49 | -0.52 | — | — |
| EPS, diluted | -0.63 | -0.33 | -0.49 | -0.52 | — | — |
| Shares, diluted (wtd. avg.) | 141.7M | 138.8M | 111.3M | 96.6M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $11.3M | $121.3M | $68.8M | — | — | — |
| Short-term investments | $73.8M | $26.0M | — | — | — | — |
| Receivables | $0 | $972.0K | $290.0K | — | — | — |
| Total current assets | $118.7M | $187.4M | $103.2M | — | — | — |
| Property, plant and equipment | $1.6M | $1.8M | $1.9M | — | — | — |
| Goodwill | $10.6M | $9.4M | $10.0M | $9.7M | — | — |
| Other intangibles | $288.0K | $312.0K | — | — | — | — |
| Total assets | $131.4M | $202.6M | $119.4M | — | — | — |
| Total current liabilities | $13.6M | $16.8M | $22.3M | — | — | — |
| Total liabilities | $69.1M | $68.6M | $97.5M | — | — | — |
| Retained earnings | -$562.6M | -$474.0M | -$431.9M | — | — | — |
| Total equity | $62.3M | $134.0M | $22.0M | $27.2M | $12.4M | — |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$62.3M | -$67.6M | -$49.5M | -$57.0M | — | — |
| Depreciation and amortisation | $312.0K | $336.0K | $369.0K | $379.0K | — | — |
| Stock-based compensation | $8.1M | $16.3M | $16.3M | $12.7M | — | — |
| Capital expenditure | $55.0K | $211.0K | $56.0K | $173.0K | — | — |
| Investing cash flow | -$48.0M | -$22.0M | $19.3M | -$20.5M | — | — |
| Financing cash flow | $15.0K | $142.1M | $31.9M | $52.6M | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-191786.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $21.7M | $31.6M | $43.3M | $559.0K |
| Gross profit | — | — | $8.2M | $18.8M | $31.4M | $344.0K |
| Net income | — | — | -$50.3M | -$54.2M | -$45.3M | -$88.6M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event Item 8.01
- Material agreement signed Item 1.01
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |